2019 American Transplant Congress
Safety Outcomes in Elderly Patients Who Receive Alemtuzumab Induction for Kidney Transplant
Ochsner Clinic Foundation, New Orleans, LA
*Purpose: As a consequence of natural immunosenescence, elderly patients may not require as potent immunosuppression as their younger counterparts. Optimal induction regimens in this population,…2019 American Transplant Congress
Use of an Ideal Body Weight-Based Rabbit Anti-Thymocyte Globulin Dosing Protocol in Kidney Transplant Recipients to Decrease Cost and Maintain Outcomes at a Large Academic Medical Center
1Pharmacy, Mayo Clinic, Rochester, MN, 2Transplantation Surgery, Mayo Clinic, Rochester, MN
*Purpose: This quality improvement study sought to assess if rejection post-transplant was increased following implementation of an ideal body weight (IBW)-based dosing protocol for patients…2019 American Transplant Congress
Is Alemtuzumab Induction Safe In Septuagenarians Undergoing Deceased Donor Kidney Transplantation?
Wake Forest Baptist Medical Center, Winston-Salem, NC
*Purpose: Alemtuzumab induction in septuagenarians is controversial but understudied.*Methods: Single center retrospective review of adult deceased donor kidney transplant (KT) recipients receiving single dose (30…2019 American Transplant Congress
Induction Type Does Not Influence Kidney Graft or Patient Survival in Recipients with a Previous Heart Transplant in the United States
*Purpose: Induction regimens for kidney transplant (KT) in heart recipients vary widely among transplant centers. We sought to examine the impact of kidney induction type…2019 American Transplant Congress
Reduced Intensity Induction Therapy in Patients Undergoing Repeat Kidney Transplants
Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil
*Purpose: We hypothesized that patients without donor-specific antibodies (DSA) undergoing repeat transplants could receive lower doses of antithymocyte globulin induction (rATG), without compromising efficacy and…2019 American Transplant Congress
Depletional Induction Therapy in Non-Human Primates – Preclinical Modeling of Polyclonal Depletion with Rhesus-Specific ATG
*Purpose: Antithymocyte globulins (ATG) have been used in transplantation since the late 1960s to prevent and treat acute allograft rejection. Over the past decade, induction…2019 American Transplant Congress
Outcomes of Reduced Thymoglobulin Induction Dosing in Elderly Kidney Transplant Recipients at a Steroid Sparing Center
Pharmacy, NewYork-Presbyterian, New York, NY
*Purpose: Studies have demonstrated a mortality benefit with kidney transplantation (KT) in elderly patients, but there is little consensus over optimal immunosuppression. Older KT recipients…2019 American Transplant Congress
Fatal Graft versus Host Disease in Liver Transplantation. An Analysis of UNOS Registry
*Purpose: Graft-versus-host disease (GVHD) after liver transplant is a rare complication. This study aimed to analyze the UNOS registry to identify risk factors for fatal…2018 American Transplant Congress
Induction Agents and Post-Transplant Malignancies in Kidney Transplants: An Examination of Outcomes at a Large Volume Center over 20 Years
Division of Transplant Surgery, University of Wisconsin, Madison, WI.
Introduction: Induction agents have a profound effect on the immune milieu at the time of kidney transplantation. However, evaluation of their long-term effects on graft…2018 American Transplant Congress
Optimal Anti-Thymocyte Globulin Dose for Induction Immunosuppression in Kidney Transplantation
Organ Transplant Program, Swedish Medical Center, Seattle, WA.
Anti-thymocyte globulin (ATG) is used as induction immunosuppression in kidney transplantation to prevent allograft rejection. ATG causes dose-dependent lymphocyte depletion, yet optimal dose is unknown.…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 31
- Next Page »